Phase II ELMWOOD trial shows elafibranor is well tolerated and improves liver biochemistry and pruritus in primary sclerosing ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Statin therapy decreased the risk for developing acute cholangitis among patients with primary ...

IgG4-related hepatobiliary diseases (IgG4-HBD) are part of a systemic fibroinflammatory condition, termed IgG4-related disease. IgG4-HBD includes IgG4-related sclerosing cholangitis (IgG4-SC) and IgG4 ...

Nebokitug is a lab-engineered antibody that targets a molecule called CCL24, a signaling protein known to drive inflammation ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Quantitative magnetic resonance cholangiopancreatography may help assess changes in the biliary tree ...

A multicenter study led by UC Davis Health has tested a new treatment designed to improve care for people with a rare liver disease called primary sclerosing cholangitis. Researchers learned that an ...

The new therapy strategy for primary sclerosing cholangitis, a liver disease that at present still cannot be cured with medication, shows initial measureable success with the nor-ursodeoxycholic acid ...

Although a colonoscopy for the evaluation of IBD and the surveillance of colitis-associated neoplasia should be performed at the time of the diagnosis of primary sclerosing cholangitis (PSC), the ...

The clinical research and development program will be conducted in collaboration with the Stravitz–Sanyal Institute for Liver Disease and Metabolic Health Virginia Commonwealth University. TEL AVIV, ...